Jazz Pharmaceuticals revenue and financials
$231.39Change from previous close: −1.97%Absolute change: −$4.65
In the fiscal year ended December 2025, Jazz Pharmaceuticals reported revenue of $4.27B (+4.88% year over year). The net loss was $356.15M.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +4.88%
- 2025 vs 2024
- Net margin
- -8.3%
- 2024: 13.8%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 11,659 | 12,012 | 11,393 | 10,835 | 12,299 | 6,536 | 5,539 | 5,203 | 5,124 | 4,800 |
| Current assets | 4,166 | 4,629 | 3,435 | 2,606 | 2,611 | 2,840 | 1,630 | 1,234 | 968 | 748 |
| Cash and equivalents | 1,392 | 2,413 | 1,506 | 881 | 591 | 1,058 | 637 | 310 | 386 | 366 |
| Short-term investments | 1,050 | 580 | 120 | 0.0 | — | — | — | — | — | — |
| Receivables | 831 | 717 | 706 | 651 | 563 | — | — | — | — | — |
| Inventory | 417 | 480 | 597 | 714 | 1,073 | — | — | — | — | — |
| Net property, plant and equipment | 259 | 227 | 235 | 301 | 343 | — | — | — | — | — |
| Goodwill | 1,829 | 1,716 | 1,753 | 1,693 | 1,828 | 958 | 920 | 928 | 948 | 894 |
| Other intangible assets | 4,430 | 4,756 | 5,418 | 5,794 | 7,152 | — | — | — | — | — |
| Long-term investments | 4.3 | 4.3 | 4.7 | 5.5 | 5.0 | — | — | — | — | — |
| Current liabilities | 2,243 | 1,039 | 1,537 | 933 | 809 | 654 | 364 | 345 | 294 | 257 |
| Accounts payable | 122 | 77.9 | 103 | 90.8 | 100 | — | — | — | — | — |
| Long-term debt | 5,358 | 6,109 | 5,713 | 5,724 | 6,050 | 2,095 | 1,607 | 1,596 | 1,581 | 2,030 |
| Total debt | 5,424 | 6,162 | 5,792 | 5,812 | — | — | — | — | — | — |
| Total liabilities | 7,341 | 7,919 | 7,656 | 7,750 | 8,333 | — | — | — | — | — |
| Total equity (incl. minority) | 4,319 | 4,094 | 3,737 | 3,086 | 3,965 | — | — | — | — | — |
| Retained earnings | 646 | 1,127 | 879 | 734 | 830 | — | — | — | — | — |